0
0.5
1
1.5
2+
Hospitalization or ER visit
84%
Improvement
Relative Risk
Bamlanivimab/e.. Lilly et al. EARLY TREATMENT RCT
Is early treatment with bamlanivimab/etesevimab beneficial for COVID-19?
RCT 268 patients in the USA
Fewer hosp./ER visits with bamlanivimab/etesevimab (p=0.049)
c19early.org
Lilly, Press Release, October 2020
Favors bamlanivimab/e..
Favors control